Swedish Orphan Biovitrum Ab (publ)

Affibody Ab

Ipc Research, LLC

Swedish Orphan Biovitrum Ab (pub)

Swedish Orphan Biovitrum Ab

Patrik Strömberg

Elin Gunneriusson

Joachim Feldwisch

Charlotta Berghard

Magnus Berglund

Malin Lindborg

Erik Nordling

Joakim Nilsson

Olle Hernell

Birgitta Olsson

Lennart Svensson

Kristina Timdahl

Maria Öhman

Marten Vågerö

Maria ÖHman

Mårten Vagerö

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.

Polypeptides binding to human complement C5

The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EXXXAXXEIXXLPNLXXXQXXAFIXXLXXXPXQSXXLLXE AKKLXXXQ (SEQ ID NO: 55). The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EXXXAXXEIXXLPNLXXXQXXAFIXXLXXXPXQSXXLLXE AKKLXXXQ (SEQ ID NO: 55), and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.

Binding polypeptides having a mutated scaffold

The invention relates to a polypeptide capable of binding human complement component 5 (C5), said polypeptide comprising the amino acid sequence wherein [BM] is a C5 binding motif; [L2] is an interconnecting loop; Xis selected from A and S; Xis selected from N and E; Xis selected from A, S and C; Xis selected from E, N and S; Xis selected from D, E and S, provided that Xis not D when Xis N; and Xis selected from A and S.

Stable polypeptides binding to human complement C5

The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EXXXA XXEID XLPNL XXXQW XAFIXXLXD, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.

The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.

Method to increase the absorption of unsaturated fatty acids by human infants

The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds. In another aspect, the present invention relates to methods to: (X) protect the small bowel mucosa of a human infant from damage; to (Y) protect an immature intestinal epithelium of a human infant from the deleterious effects of incompletely digested and/or excess fat and/or lipid; and/or to (Z) limit accumulation of incompletely digested and/or excess fat and/or lipid in the ileum of a human infant; said methods in each case comprising the step of enteral administration of rhBSSL.

Method to increase the growth velocity of human infants

Growing community of inventors

Sollentuna, Sweden

Patrik Strömberg